相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors
Alena M. Pfeil et al.
BMC CANCER (2014)
Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel
C. Vulsteke et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Hyaluronan Synthase 3 Variant and Anthracycline-Related Cardiomyopathy: A Report From the Children's Oncology
Xuexia Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Cardiac dose sparing and avoidance techniques in breast cancer radiotherapy
Chirag Shah et al.
RADIOTHERAPY AND ONCOLOGY (2014)
Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors
Adedayo A. Onitilo et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2014)
Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC)
C. Vulsteke et al.
ANNALS OF ONCOLOGY (2013)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2013)
Association of Anthracycline-Related Cardiac Histological Lesions With NADPH Oxidase Functional Polymorphisms
Almudena Cascales et al.
ONCOLOGIST (2013)
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children
H. Visscher et al.
PEDIATRIC BLOOD & CANCER (2013)
Breast Cancer Treatment and Adverse Cardiac Events: What Are the Molecular Mechanisms?
Laura Roca-Alonso et al.
CARDIOLOGY (2012)
ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia
Agnes F. Semsei et al.
CELL BIOLOGY INTERNATIONAL (2012)
Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children
Henk Visscher et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes-A Report From the Children's Oncology Group
Javier G. Blanco et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing
Joke Reumers et al.
NATURE BIOTECHNOLOGY (2012)
Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood
Vladan Rajić et al.
LEUKEMIA & LYMPHOMA (2009)
A pilot study to investigate the feasibility and cardiac effects of pegylated liposomal doxorubicin (PL-DOX) as adjuvant therapy in medically fit elderly breast cancer patients
Hans Wildiers et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
Strain Rate Imaging Detects Early Cardiac Effects of Pegylated Liposomal Doxorubicin as Adjuvant Therapy in Elderly Patients with Breast Cancer
Ruxandra Jurcut et al.
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY (2008)
Purposeful selection of variables in logistic regression
Zoran Bursac et al.
SOURCE CODE FOR BIOLOGY AND MEDICINE (2008)
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer
Mary C. Pinder et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors
Melissa M. Hudson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Trastuzumab treatment and the risk of central nervous system (CNS) metastases
M. C. Pinder et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management
Elly Barry et al.
EXPERT OPINION ON PHARMACOTHERAPY (2007)
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients:: The FNCLCC PACS 01 trial
Henri Roche et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Stratified false discovery control for large-scale hypothesis testing with application to genome-wide association studies
Lei Sun et al.
GENETIC EPIDEMIOLOGY (2006)
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity
L Wojnowski et al.
CIRCULATION (2005)
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
AU Buzdar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cardiovascular complications of cancer therapy - Diagnosis, pathogenesis, and management
ETH Yeh et al.
CIRCULATION (2004)
Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children:: a systematic review
LCM Kremer et al.
ANNALS OF ONCOLOGY (2002)
The human ATP-binding cassette (ABC) transporter superfamily
M Dean et al.
GENOME RESEARCH (2001)
Cardiotoxicity of chemotherapeutic agents - Incidence, treatment and prevention
VB Pai et al.
DRUG SAFETY (2000)
分享论文
